Literature DB >> 10692032

Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA.

S Oehen1, T Junt, C López-Macías, T A Kramps.   

Abstract

In this study, we investigated the potential of a DNA vaccine expressing the minimal cytotoxic T lymphocyte (CTL) epitope gp33 of the lymphocytic choriomeningitis virus glycoprotein to protect against infection of a non-lymphoid organ and compared this to protection against a systemic infection. Furthermore, since immune stimulatory sequences have been shown to augment CTL responses, we examined the capacity of CpG DNA to enhance CTL memory. The data show that DNA vaccination with a gp33-based gene construct induced short-lived gp33-specific CTL which protected against a systemic infection but not against a peripheral infection. Immune stimulatory sequences were incapable of either prolonging CTL memory or promoting protection against infection of a peripheral organ.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10692032      PMCID: PMC2327147          DOI: 10.1046/j.1365-2567.2000.00950.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides.

Authors:  R Weeratna; C L Brazolot Millan; A M Krieg; H L Davis
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1998-08

2.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.

Authors:  H L Davis; R Weeratna; T J Waldschmidt; L Tygrett; J Schorr; A M Krieg; R Weeranta
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

Review 3.  Gene vaccination: plasmid DNA is more than just a blueprint.

Authors:  H Tighe; M Corr; M Roman; E Raz
Journal:  Immunol Today       Date:  1998-02

4.  CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants.

Authors:  G B Lipford; M Bauer; C Blank; R Reiter; H Wagner; K Heeg
Journal:  Eur J Immunol       Date:  1997-09       Impact factor: 5.532

5.  DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination.

Authors:  F Rodriguez; L L An; S Harkins; J Zhang; M Yokoyama; G Widera; J T Fuller; C Kincaid; I L Campbell; J L Whitton
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 6.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

7.  Contribution of CpG motifs to the immunogenicity of DNA vaccines.

Authors:  D M Klinman; G Yamshchikov; Y Ishigatsubo
Journal:  J Immunol       Date:  1997-04-15       Impact factor: 5.422

8.  Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.

Authors:  G J Weiner; H M Liu; J E Wooldridge; C E Dahle; A M Krieg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

9.  Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice.

Authors:  D L Larsen; N Dybdahl-Sissoko; M W McGregor; R Drape; V Neumann; W F Swain; D P Lunn; C W Olsen
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

10.  DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen.

Authors:  S Sun; H Kishimoto; J Sprent
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

View more
  6 in total

1.  Intralymphatic immunization enhances DNA vaccination.

Authors:  K J Maloy; I Erdmann; V Basch; S Sierro; T A Kramps; R M Zinkernagel; S Oehen; T M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 2.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.

Authors:  Luisa Cervantes-Barragan; Roland Züst; Reinhard Maier; Sophie Sierro; Jozef Janda; Frederic Levy; Daniel Speiser; Pedro Romero; Pierre-Simon Rohrlich; Burkhard Ludewig; Volker Thiel
Journal:  MBio       Date:  2010-09-14       Impact factor: 7.867

4.  DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response.

Authors:  Luciana Barros de Arruda; Priya R Chikhlikar; J Thomas August; Ernesto T A Marques
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

5.  SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens.

Authors:  Vandana Gupta; Tani M Tabiin; Kai Sun; Ananth Chandrasekaran; Azlinda Anwar; Kun Yang; Priya Chikhlikar; Jerome Salmon; Vladimir Brusic; Ernesto T A Marques; Srinivasan N Kellathur; Thomas J August
Journal:  Virology       Date:  2006-01-04       Impact factor: 3.616

6.  Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines.

Authors:  Roland Züst; Luisa Cervantes-Barragán; Thomas Kuri; Gjon Blakqori; Friedemann Weber; Burkhard Ludewig; Volker Thiel
Journal:  PLoS Pathog       Date:  2007-08-10       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.